Journal: Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring

Article Title: Evaluation of harmonization methods to mitigate assay and cohort effects in plasma p‐tau217

doi: 10.1002/dad2.70518

Figure Lengend Snippet: Participant demographic and clinical characteristics.

Article Snippet: The Fujirebio Lumipulse G p‐tau217 assay included in this study is part of the U.S. Food and Drug Administration (FDA)–cleared Lumipulse G pTau217/β‐Amyloid 1‐42 Plasma Ratio test for the initial evaluation of AD.

Techniques:

Journal: Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring

Article Title: Evaluation of harmonization methods to mitigate assay and cohort effects in plasma p‐tau217

doi: 10.1002/dad2.70518

Figure Lengend Snippet: Distributions of ln(p‐tau217) across assay platforms before and after harmonization. Density plots of ln(p‐tau217) values are shown for each assay platform in the ADNI (top) and HCP (bottom) cohorts before (labeled as Raw) and after application of each harmonization method. Colored dashed vertical lines represent the assay‐specific mean. The Z‐score‐based methods represent standard deviation units from the mean. CentiMarker uses a 0−100 scale, with 0 representing normal levels and 100 representing nearly maximally abnormal levels. ADNI, Alzheimer's Disease Neuroimaging Initiative; HCP, Human Connectome Project; ln(p‐tau217), natural log‐transformed tau phosphorylated at threonine 217.

Article Snippet: The Fujirebio Lumipulse G p‐tau217 assay included in this study is part of the U.S. Food and Drug Administration (FDA)–cleared Lumipulse G pTau217/β‐Amyloid 1‐42 Plasma Ratio test for the initial evaluation of AD.

Techniques: Labeling, Standard Deviation, Transformation Assay

Journal: Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring

Article Title: Evaluation of harmonization methods to mitigate assay and cohort effects in plasma p‐tau217

doi: 10.1002/dad2.70518

Figure Lengend Snippet: Coefficient estimates of diagnosis and assay platform before and after harmonization. Linear mixed models were fit for each harmonization method within each ADNI (blue) and HCP (red) cohort. Each model included a subject‐specific random intercept and fixed effects for diagnostic group, assay platform, age, sex, race, APOE ε4 status, and Aβ‐positivity status. The ADNI model additionally adjusted for years of education. Points represent regression coefficients (β) and horizontal lines denote 95% confidence intervals (CIs). Filled circles indicate statistically significant associations ( p < 0.05), whereas open circles indicate non‐significant associations. The diagnosis coefficient represents the adjusted mean difference in ln(p‐tau217) between cognitively impaired and cognitively unimpaired participants. Assay coefficients represent adjusted mean differences relative to the ALZpath assay (reference). The Z‐score−based methods express differences in standardized units and CentiMarker expresses differences in CentiMarker units. Aβ, amyloid beta; ADNI, Alzheimer's Disease Neuroimaging Initiative; APOE , apolipoprotein E; CI, confidence interval; HCP, Human Connectome Project; ln(p‐tau217), natural log‐transformed tau phosphorylated at threonine 217.

Article Snippet: The Fujirebio Lumipulse G p‐tau217 assay included in this study is part of the U.S. Food and Drug Administration (FDA)–cleared Lumipulse G pTau217/β‐Amyloid 1‐42 Plasma Ratio test for the initial evaluation of AD.

Techniques: Biomarker Discovery, Diagnostic Assay, Transformation Assay

Journal: Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring

Article Title: Evaluation of harmonization methods to mitigate assay and cohort effects in plasma p‐tau217

doi: 10.1002/dad2.70518

Figure Lengend Snippet: Estimated effects of diagnosis and cohort before and after harmonization. Multiple linear regression models were fit for each harmonization method within each assay: ALZpath (blue), Fujirebio (green), and Janssen (orange). Each model included diagnostic group, cohort, age, sex, race, APOE ε4 status, and Aβ‐positivity status covariates. The ADNI model additionally adjusted for years of education. Points represent regression coefficients (β) and horizontal lines denote 95% confidence intervals. Filled circles indicate statistically significant associations ( p < 0.05), whereas open circles indicate non‐significant associations. Z‐score‐based methods express differences in standardized units and CentiMarker expresses differences in CentiMarker units. ADNI, Alzheimer's Disease Neuroimaging Initiative; CI, confidence interval; HCP, Human Connectome Project; ln(p‐tau217) = natural log‐transformed tau phosphorylated at threonine 217.

Article Snippet: The Fujirebio Lumipulse G p‐tau217 assay included in this study is part of the U.S. Food and Drug Administration (FDA)–cleared Lumipulse G pTau217/β‐Amyloid 1‐42 Plasma Ratio test for the initial evaluation of AD.

Techniques: Biomarker Discovery, Diagnostic Assay, Transformation Assay

Journal: Tropical Animal Health and Production

Article Title: Routine serum biomarkers and lightgbm modeling for the diagnosis of abomasal ulcers in culled dairy cows

doi: 10.1007/s11250-026-05432-9

Figure Lengend Snippet: Inflammatory, serum biochemical, and hematological variables in dairy cows with and without abomasal ulcers

Article Snippet: Analytes included fibrinogen (Kaneko and Smith ), urea (BioSystems , 11541), creatinine (Labtest , 96–300), total protein (Labtest , 99–250), albumin (Labtest , 19–250), calcium (BioSystems , 11570), aspartate aminotransferase (AST) (BioSystems ,11531), gamma glutamyl transferase (GGT) (BioSystems , 11520), creatine kinase (CK) (Diasys , 116019910021); and plasma beta-hydroxybutyrate (Randox , RB 1007).

Techniques: